表紙:臨床試験部門のスコアカード - テーマ別分析
市場調査レポート
商品コード
1034674

臨床試験部門のスコアカード - テーマ別分析

Clinical Trials Sector Scorecard - Thematic Research

出版日: | 発行: GlobalData | ページ情報: 英文 24 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
臨床試験部門のスコアカード - テーマ別分析
出版日: 2021年10月29日
発行: GlobalData
ページ情報: 英文 24 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

製薬業界が臨床試験を実施する際に直面する主な課題には、複雑で非効率的な試験デザイン、患者の募集・維持率の低下、高コストにつながる遅延、データの整合性やプライバシーの問題などがあります。

これらの問題を克服するためには、臨床試験のプロセスを改善する技術に投資する必要があります。リモート患者モニタリング (RPM) 、遠隔医療、ウェアラブル、モバイルヘルスなどが含まれます。また、クラウドコンピューティング、サイバーセキュリティ、ブロックチェーンなどの新興技術の利用により、臨床試験の患者データを安全に保存・分析することが可能になる一方で、人工知能 (AI) を利用することで、臨床試験のデザインや募集を強化することができます。

当レポートでは、臨床試験部門における主要企業のトップダウンかつ総合的な将来の見通し (今後2~4年間) を提供しています。

目次

目次

  • エグゼクティブサマリー
  • イントロダクション
  • 製薬企業のテーママップ
  • 臨床試験のスコアカード
  • 企業別
  • テーマ別
  • 評価別
  • テーマ別の調査手法
  • 製薬企業スコアの生成方法
  • 関連レポート
  • 著者について
  • GlobalDataについて
目次
Product Code: GDHCHT293

Some of the key challenges that the pharma industry faces when running clinical trials include complex and inefficient trial design, low patient recruitment and retention rates, delays leading to high costs, and data integrity and privacy issues.

To overcome these issues, the industry must invest in technologies that improve clinical trial processes. This includes those that facilitate the implementation of virtual trials, a key trend in the pharma industry as a result of the ongoing disruption to clinical trials due to COVID-19 lockdowns and social distancing measures. These technologies include remote patient monitoring (RPM), telemedicine, wearables, and mobile health. In addition, the use of emerging technologies such as cloud computing, cybersecurity, and blockchain allow for patient data from trials to be stored and analyzed safely, whereas artificial intelligence (AI) can be used to enhance trial design and recruitment.

Developing rare disease drugs and improving trial participant diversity are seen as two important aspects of social sustainability. In rare disease, there is often little incentive to develop therapies as the patient populations are so small. However, orphan drug designations provide many benefits such as enhanced regulatory processes, fee waiving, tax benefits, and market exclusivity.

Our thematic scoring methodology is designed to identify tomorrow's leaders rather than today's incumbents, based on their competitive position in the 10 most important themes impacting the landscape.

Scope

  • GlobalData's Clinical Trials Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the clinical trials sector over the next two to four years.
  • These themes are Virtual Care, Rare Disease, Orphan Designated Drugs, Strategic Alliances, Real-world Evidence, AI, ESG, Cybersecurity, Cloud Computing, and Blockchain.
  • The scorecard includes 54 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.

Reasons to Buy

  • Identify the key clinical trial themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

Table of Contents

  • Executive Summary
  • Introduction
  • Pharma Theme Map
  • Clinical Trials Scorecard
  • Company Screen
  • Thematic Screen
  • Valuation Screen
  • Our Thematic Research Methodology
  • How Our Pharma Scores Are Generated
  • Related Reports
  • About the Authors
  • About GlobalData